Converging indications of aldosterone antagonists (Spironolactone and Eplerenone): A narrative review of safety profiles topical collection on antihypertensive agents: Mechanisms of drug action

Current Hypertension Reports

Volumn 16, Issue 2, 2014, Pages

  Danjuma, Mohammed I ^a,c   Mukherjee, Ipshita ^b   Makaronidis, Janine ^c   Osula, Serge ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c STEPPING HILL HOSPITAL   (United Kingdom)

^d WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aldosterone; Eplerenone; Mineralocorticoid receptor antagonists; Spironolactone

Indexed keywords

ALDOSTERONE ANTAGONIST; EPLERENONE; MINERALOCORTICOID ANTAGONIST; PLACEBO; SPIRONOLACTONE; DRUG DERIVATIVE;

ARTICLE; BREAST TENDERNESS; CARDIOVASCULAR RISK; CLINICAL PHARMACOLOGY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; KIDNEY FAILURE; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; ANIMAL; REVIEW;

ANIMALS; HUMANS; HYPERKALEMIA; HYPERTENSION; MINERALOCORTICOID RECEPTOR ANTAGONISTS; SPIRONOLACTONE;

EID: 84893720936     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0414-8     Document Type: Article

References (64)

1. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. New Eng J Med. 2011;364:11-21. This report established the clinical utility of Eplerenone in patients with heart failure and mild symptoms.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-17. This paper was the first to establish the efficacy and safety of Spironolactone in patients with heart failure.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
4. Parthasarathy HK, Menard J, White W, et al. A double blind, randomized study comparing the antihypertensive effect of Eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011;29:980-99.
5. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA guideline update for the diagnosis and management of chronic heart failure in the adult. www.acc.org/clinical/guidelines/failure/index
6. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:2217-8.
7. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. National Institute for Clinical Excellence. Clinical guidelines, CG108 - Issued: (2010)
8. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and Spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-41.
9. Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalemia in congestive heart failure patients using ACE inhibitors and Spironolactone. Nephrol Dial Transplant. 2003;18:1814-9.
10. Pitt B, Bakris G, Ruilope L, DiCarlo L, Mukherjee R, on Behalf of the EPHESUS Investigators. Serum potassium and clinical outcomes in the Eplerenone post acute myocardial infarction heart failure efficacy and survival study (EPHESUS). Circulation. 2008;118:1643-50.
11. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709-16.
12. Robert V, VenThiem N, Cheav SL, Mouas CB, Swynghedauw Delcayre C. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994;24:30-6.
13. Silvestre J, Heymes C, Abdesalam O, Valerie R, Delcayre C, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999;99(20):2694-701.
14. Chai W, Garrelds IM, de Vries R, Batenburg WW, van Kats JP, et al. Non genomic effects of aldosterone in the human heart: interaction with angiotensin II. Hypertension. 2005;46:701-6.
15. Gordon RD, Ziesak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon: 12 % incidence among antihypertensive drug trail volunteers. Clin Exp Pharmacol Physiol. 1993;20:296-8.
16. Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Pinto M, Huete A, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-7.
17. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J. 2000;90:394-400.
18. Brilla C, Weber K. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 1992;26:671-7.
19. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K. Effect of Eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure. Am Heart J. 2010;160(5):915-21.
20. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796-802.
21. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, et al. Production of aldosterone in isolated rat blood vessels. Hypertension. 1995;25:170-3.
22. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96:643-50.
23. de Gasparo M, Joss U, Ramjoue HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240(2):650-6.
24. Mihailidou AS, Le Loan TY, Mardini M, Funder JW. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction. Hypertension. 2009;54(6):1306-12.
25. Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29(4):342-7.
26. Pharmaceuticals P. Eplerenone package insert
27. Pharmaceuticals M. Spironolactone package insert
28. Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107(19):2512-8.
29. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10(1):23.
30. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L. Involvement of CYP3A in the metabolism of Eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002;30(12):1344-51.
31. De Gasparo M, Whitebread SE, Preiswerk G, et al. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem. 1989;32(1B):223-7.
32. McKenna C, Burch J, Suekarran S, Walker S, Palmer S. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for post-myocardial infarction heart failure. Health Tech Assess. 2010;14(24):1-162.
33. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418-24.
34. Juurlink DN, Mamdani M, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalaemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-51.
35. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of Spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-4.
36. Ko DT, Juurlink DN, Mamdani MM, You JJ, Wang JT, Donovan LR, et al. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study. J Card Fail. 2006;12:205-10.
37. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971-8.
38. Witham MD, Gillespie ND, Struthers AD. Tolerability of spironolactone in patients with chronic heart failure: a cautionary message. Br J Clin Pharmacol. 2004;58:554-7.
39. Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston collaborative drug surveillance program. JAMA. 1973;225:40-3.
40. Marciniak TA. U.S. food and drug administration, center for drug evaluation and research. (Japanese dose ranging study) Clinical review for sNDA 21-437 Inspra Tablets (Parts 1-4) 2003.
41. Eschalier R, McMurray JJV, Swedberg K, van Veldhuisen DJ, Pitt B, et al. Safety and efficacy of Eplerenone in patients at high risk for hyperkalemia and/or worsening renal function. Analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). J Am Coll Cardiol. 2013;62(17):1585-93. This is a potentially practice changing report as it has established the safety of Eplerenone in a population physicians have hitherto been reluctant to prescribe; i.e. cohorts with CKD or at high risk of hyperkalaemia.
42. Marcy TR, Ripley TL. Aldosterone antagonists in the treatment of heart failure. Am J Health Syst Pharm. 2006;63(1):49-58.
43. Delyani J, Myles K, Funder J. Eplerenone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens. 1998;11:94A.
44. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-5.
45. Sligl W, McAlister FA, Ezekowitz J, Armstrong PW. Usefulness of spironolactone in a specialized heart failure clinic. Am J Cardiol. 2004;94(4):443-7.
46. Sica D, Flack J. Treatment considerations with aldosterone receptor antagonists. J Clin Hypertens. 2011;13:65-9.
47. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-10.
48. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of Spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-45.
49. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925-30.
50. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147-52.
51. Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. AJH. 2002;15:333-9.
52. Schersten B, Thulin T, Kuylenstierna J, Engstrom M, Nilsson G, et al. Clinical and biochemical effects of Spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension. 1980;2:672-9.
53. Williams G, Burgess E, Kolloch R, Ruilope L, Niegowska J, Kipnes M, et al. Efficacy of Eplerenone versus enalapril as Monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990-6.
54. Flack JM, Oparil S, Pratt JH, Roniker B, Saunders E, et al. Efficacy and tolerability of Eplerenone and Losartan in hypertensive black and white patients. J Am Coll Cardiol. 2003;41:1148-55.
55. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika A, Mikhailidis D, et al. Spironolactone versus Eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008;9:509-15.
56. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmaco Kinet. 2002;41(12):913-58.
57. Searle GD. Inspra (Eplerenone) package insert. 2003.
58. Lawson DH, O'Connor PC, Jick H. Drug attributed alterations in potassium handling in congestive cardiac failure. Eur J Clin Pharmacol. 1982;23:21-5.
59. Shah KB, Gottlieb SS. Laboratory monitoring for spironolactone in congestive heart failure. Cardiol Rev. 2006;23:35-7.
60. Nassiacos D, Meloni S. Tolerability and efficacy of aldosterone inhibition with canrenone in heart failure: the real-world experience of an outpatient heart failure clinic. Ital Heart J. 2005;6 Suppl 1:51S-65S.
61. Yano Y, Hoshide S, Tamaki N, Nagata M, Sasaki K. Eplerenone treatment (JET) study: efficacy of Eplerenone added to renin-angiotensin blockade in elderly hypertensive patients. J Renin-Angiotensin-Aldosterone Syst. 2011;12(3):340-7.
62. Sato A, Fukuda S. Clinical effects of Eplerenone, a selective aldosterone blocker in Japanese patients with essential hypertension. J Hum Hypertens. 2010;24:387-94.
63. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips R, Roniker B, et al. Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-8.
64. White W, Duprez D, St Hillaire R, Krause S, Roniker B. Effects of the selective aldosterone blocker Eplerenone versus the calcium antagonist Amlodipine in systolic hypertension. Hypertension. 2003;41:1021-6.